Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Betulinic Acid Improves Cardiac-Renal Dysfunction Caused by Hypertrophy through Calcineurin-NFATc3 Signaling.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI Publishing
    • الموضوع:
    • نبذة مختصرة :
      Cardiac hypertrophy can lead to congestive heart failure and is a leading cause of morbidity and mortality worldwide. In recent years, it has been essential to find the treatment and prevention of cardiac hypertrophy. Betulinic acid (BA), the main active ingredient in many natural products, is known to have various physiological effects. However, as the potential effect of BA on cardiac hypertrophy and consequent renal dysfunction is unknown, we investigated the effect of BA on isoprenaline (ISO)-induced cardiac hypertrophy and related signaling. ISO was known to induce left ventricular hypertrophy by stimulating the β2-adrenergic receptor (β 2 AR). ISO was injected into Sprague Dawley rats (SD rats) by intraperitoneal injection once a day for 28 days to induce cardiac hypertrophy. From the 14th day onwards, the BA (10 or 30 mg/kg/day) and propranolol (10 mg/kg/day) were administered orally. The study was conducted in a total of 5 groups, as follows: C, control; Is, ISO (10 mg/kg/day); Pr, positive-control, ISO + propranolol (10 mg/kg/day); Bl, ISO + BA (10 mg/kg/day); Bh, ISO + BA (30 mg/kg/day). As a result, the total cardiac tissue and left ventricular tissue weights of the ISO group increased compared to the control group and were significantly reduced by BA treatment. In addition, as a result of echocardiography, the effect of BA on improving cardiac function, deteriorated by ISO, was confirmed. Cardiac hypertrophy biomarkers such as β-MHC, ANP, BNP, LDH, and CK-MB, which were increased by ISO, were significantly decreased by BA treatment. Also, the cardiac function improvement effect of BA was confirmed to improve cardiac function by inhibiting calcineurin/NFATc3 signaling. Renal dysfunction is a typical complication caused by cardiac hypertrophy. Therefore, the study of renal function indicators, creatinine clearance (Ccr) and osmolality (BUN) was aggravated by ISO treatment but was significantly restored by BA treatment. Therefore, it is thought that BA in cardiac hypertrophy can be used as valuable data to develop as a functional material effective in improving cardiac-renal dysfunction.
    • References:
      Mol Med Rep. 2017 Nov;16(5):6320-6325. (PMID: 28849070)
      Sci Signal. 2008 Jun 24;1(25):pe31. (PMID: 18577756)
      Circulation. 2013 Jul 23;128(4):388-400. (PMID: 23877061)
      Kidney Blood Press Res. 2018;43(5):1437-1450. (PMID: 30235455)
      J Cell Mol Med. 2018 Dec;22(12):6055-6067. (PMID: 30299584)
      Circ Res. 2011 Mar 4;108(5):629-42. (PMID: 21372294)
      Circ Res. 1999 Apr 2;84(6):623-32. (PMID: 10189350)
      Kidney Blood Press Res. 2019;44(5):1089-1100. (PMID: 31505490)
      Cell. 1998 Apr 17;93(2):215-28. (PMID: 9568714)
      Methods Mol Biol. 2018;1816:207-220. (PMID: 29987822)
      PLoS One. 2018 Feb 21;13(2):e0192322. (PMID: 29466442)
      Cell Signal. 2021 Nov;87:110134. (PMID: 34454008)
      Nutrients. 2017 May 28;9(6):. (PMID: 28555040)
      J Vis Exp. 2013 Apr 08;(74):. (PMID: 23608998)
      Acta Pharmacol Sin. 2021 Jul;42(7):1124-1138. (PMID: 32811965)
      Circ Res. 2013 Feb 1;112(3):498-509. (PMID: 23104882)
      Biomed Pharmacother. 2016 Dec;84:208-214. (PMID: 27657829)
      Gen Physiol Biophys. 2018 Jan;37(1):41-56. (PMID: 29424351)
      Inflammation. 2018 Mar;41(2):432-436. (PMID: 29168080)
      Kidney Int Suppl. 1997 Dec;63:S166-8. (PMID: 9407449)
      BMC Complement Altern Med. 2018 Oct 22;18(1):286. (PMID: 30348173)
      Biochem Biophys Res Commun. 2019 Feb 26;510(1):149-155. (PMID: 30683314)
      Br J Clin Pharmacol. 2018 Jan;84(1):5-17. (PMID: 28901643)
      Eur Heart J. 2012 Sep;33(17):2135-42. (PMID: 22888113)
      Fundam Clin Pharmacol. 2015 Feb;29(1):31-40. (PMID: 24689791)
      Mol Med Rep. 2017 May;15(5):2574-2582. (PMID: 28447738)
      Int J Mol Med. 2012 Dec;30(6):1365-75. (PMID: 23064753)
      Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338. (PMID: 28431779)
      JACC Heart Fail. 2018 May;6(5):376-378. (PMID: 29724362)
      J Mol Cell Cardiol. 2017 Feb;103:121-136. (PMID: 28007541)
    • Grant Information:
      2017R1A5A2015805 National Research Foundation of Korea; 2019R1I1A3A01062432 National Research Foundation of Korea
    • Contributed Indexing:
      Keywords: betulinic acid; calcineurin-NFATc3 signaling; cardiac hypertrophy; isoprenaline
    • الرقم المعرف:
      0 (Biomarkers)
      0 (NFATC Transcription Factors)
      0 (Pentacyclic Triterpenes)
      0 (transcription factor NF-AT c3)
      EC 3.1.3.16 (Calcineurin)
      L628TT009W (Isoproterenol)
      4G6A18707N (Betulinic Acid)
    • الموضوع:
      Date Created: 20211023 Date Completed: 20211118 Latest Revision: 20240226
    • الموضوع:
      20240226
    • الرقم المعرف:
      PMC8540639
    • الرقم المعرف:
      10.3390/nu13103484
    • الرقم المعرف:
      34684485